Patents Assigned to Teikoku Seiyaku Co., Ltd.
-
Patent number: 8438940Abstract: An apparatus and a method for simulatively measuring an environment in a microspace between human skin and a wound dressing. The simulative environment-measuring apparatus includes a constant temperature-and-humidity chamber (14); a heat exchanger (12) disposed in the chamber; a constant temperature water bath (10) and a pump (11) for supplying warm water to the heat exchanger; and a container (1) set on the heat exchanger. The container holds a water retentive member (2) therein, and is covered with a water vapor diffusion-controlling member (4). A microspace (6) formed between the water vapor diffusion-controlling member and a wound dressing (5) is a simulatively reproduced space between human skin and the wound dressing. A thin temperature-and-humidity sensor (7) is set in the microspace to measure temperature and humidity. When plural containers are used, the environments of plural wound dressings can be measured at once.Type: GrantFiled: February 21, 2008Date of Patent: May 14, 2013Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Makoto Takahashi, Takehiko Ohura, Yukiko Inamoto, Takashi Kamakura, Shigeyuki Inamoto
-
Patent number: 8420606Abstract: A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is a rare saccharide belonging to aldose and/or ketose. The aldose is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells. The ketose is D-psicose, and the cells are selected from the group consisting of chemokine secretion inhibitory activity sensitive cells, microglia migration inhibitory activity sensitive cells, and hypoglycemic activity sensitive cells.Type: GrantFiled: January 14, 2011Date of Patent: April 16, 2013Assignees: Fushimi Pharmaceutical Co., Ltd., Teikoku Seiyaku Co., Ltd., National University Corporation Kagawa University, Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Ken Izumori, Masaaki Tokuda, Toshifumi Itano, Osamu Miyamoto, Toshihiko Ishida, Koji Murao, Taizo Tasaka, Gan Muneuchi, Fuminori Yamaguchi, Terukazu Tanaka, Masaaki Ueki, Kazuyuki Hirooka, Tomohiko Taminato, Mohammad A. Hossain, Keiji Tsusaki, Takeo Takahashi, Mitsuhiro Nagata, Yutaka Ishida
-
Patent number: 8377476Abstract: Disclosed is a water-based adhesive skin patch which has excellent storage stability, can achieve excellent accumulation of butenafine hydrochloride contained therein on a patched area such as the skin and a nail, and has a high therapeutic effect. Specifically disclosed is a water-based adhesive skin patch containing butenafine hydrochloride, which is characterized by containing butenafine hydrochloride, glycol salicylate and propylene glycol in a water-containing gel ointment. Specifically, butenafine hydrochloride is dissolved in a mixed solution of glycol salicylate and propylene glycol, and the resulting solution is dispersed in a water-containing gel. Particularly, the mixing ratio of glycol salicylate to propylene glycol is 1:2 to 1:30.Type: GrantFiled: March 24, 2009Date of Patent: February 19, 2013Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Takashi Kamakura, Takefumi Hoshikawa, Yukiko Inamoto, Kayo Tanigawa
-
Publication number: 20130035391Abstract: An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster.Type: ApplicationFiled: December 14, 2010Publication date: February 7, 2013Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Akiko Katayama, Katsuyuki Inoo
-
Publication number: 20120330217Abstract: The present invention provides an electrode device used in iontophoresis treatment, in which an electrode layer used for introduction of medication can be contacted to a medication reservoir layer with a simple manner, and in which the medication reservoir layer can be reliably held when the medication is introduced into a skin. A main-electrode layer 3 and a sub-electrode layer 1 are secured on a substrate 6 while both the layers are being insulated from each other. The main-electrode layer 3 is intended for introduction of the medication, and the sub-electrode layer 1 is provided to hold the medication reservoir layer 5 on the substrate 6. The medication reservoir layer 5 is located on the substrate 6, so as to be in contact with the main-electrode layer 3 and the sub-electrode layer 1. The medication reservoir layer 5 is a gel containing halogen compound, and the sub-electrode layer 1 comprises a metal having a lower ionization tendency than hydrogen.Type: ApplicationFiled: December 17, 2010Publication date: December 27, 2012Applicant: TEIKOKU SEIYAKU CO., LTD.Inventor: Akihiro Hasui
-
Publication number: 20120322840Abstract: A transdermally absorbable preparation in which a basic anti-inflammatory analgesic is formulated is provided to be an external adhesive patch, which has excellent drug releasing without damaging the physical properties of a plaster. The preparation can achieve high releasing of the basic anti-inflammatory analgesic without losing the releasing of the local anesthetic. Specifically provided is a transdermally absorbable adhesive patch, which contains both the basic anti-inflammatory analgesic and the local anesthetic as the absorption promoter for the basic anti-inflammatory analgesic. The basic anti-inflammatory analgesic has the acid dissociation constant (pKa) of 7 or more. The content of the basic anti-inflammatory analgesic is from 0.1% to 10% by weight to the total weight of the drug-containing plaster, and the content of the absorption promoter is from 0.01% to 20% by weight to the total weight of the drug-containing plaster in the transdermally absorbable adhesive patch.Type: ApplicationFiled: December 14, 2010Publication date: December 20, 2012Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Akiko Katayama, Katsuyuki Inoo
-
Publication number: 20120316519Abstract: A tape preparation is provided which does not use a backing such as a plastic film, knit or a woven fabric, or a nonwoven fabric, has very high conformability to skin, and is easy to use at the time of application. There is provided a tape preparation 1 that is produced by laminating a drug-containing adhesive layer 4 on the printed ink layer 3 side of a cover film 2 with printing thereon and covering the drug-containing adhesive layer with a release film 5. In this tape preparation, the adhesive strength between the cover film and the printed ink layer is higher than the adhesive strength between the drug-containing adhesive layer and the release film, and the adhesive strength between the printed ink layer and the drug-containing adhesive layer is higher than the adhesive strength between the cover film and the printed ink layer.Type: ApplicationFiled: December 14, 2010Publication date: December 13, 2012Applicant: Teikoku Seiyaku Co., LtdInventor: Masanori Uematsu
-
Publication number: 20120309749Abstract: An adhesive patch is provided in which piroxicam is formulated as a non-steroidal anti-inflammatory analgesic. In particular, provided is a piroxicam-containing transdermally absorbable adhesive patch in which an absorption promoter to piroxicam is formulated to achieve high anti-inflammatory and analgesic effects without inhibiting releasing of these drugs. The piroxicam-containing transdermally absorbable adhesive patch contains piroxicam as a medicinal component and oxybuprocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In the piroxicam-containing transdermally absorbable adhesive patch, the content of piroxicam is from 0.1% to 5% by weight to the total weight of a drug-containing plaster and the content of oxybuprocaine or the pharmaceutically acceptable salt thereof is from 1% to 30% by weight to the total weight of the drug-containing plaster.Type: ApplicationFiled: December 14, 2010Publication date: December 6, 2012Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Akiko Katayama, Katsuyuki Inoo
-
Publication number: 20120165782Abstract: It is an object of the present inventions to produce a pharmaceutical composition for the iontophoresis wherein a drug stability is excellent, and it is easy to blend and fill up when manufactured and it is possible to manufacture at low cost. A pharmaceutical composition for an iontophoresis according to the present invention, is characterized in that the composition contains a nonionic synthetic polymer, betamethasone sodium phosphate and solvent. Furthermore, in a preferred embodiment of a pharmaceutical composition for an iontophoresis according to the present invention, the composition is characterized in that the nonionic synthetic polymer is polyvinyl alcohol (PVA). Furthermore, in a preferred embodiment of a pharmaceutical composition for an iontophoresis according to the present invention, the composition is characterized in that the mixing amount of the polyvinyl alcohol (PVA) is 0.5 to 30.0 percent by weight.Type: ApplicationFiled: July 28, 2010Publication date: June 28, 2012Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Akihiro Hasui, Takamitsu Miyagi
-
Patent number: 8183232Abstract: An external preparation containing acetylsalicylic acid or its pharmaceutically acceptable salt as an active ingredient for treating anal diseases having therapeutic activity on hemorrhoids (internal hemorrhoid, external hemorrhoid), hemorrhoidal disease owing to anal fissure and other anal diseases together with activity on pain and pruritus.Type: GrantFiled: February 17, 2004Date of Patent: May 22, 2012Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Yukiko Inamoto, Seiichiro Kawabata, Mitsuhiro Kawada
-
Patent number: 8124122Abstract: Provided herein is a female hormone-containing patch wherein an active ingredient is highly soluble in a pressure-sensitive adhesive layer and the active ingredient is not adsorbed to a backing, and the patch per se can follow the irregularities on the skin surface or body movements. The patch is an external patch containing, as a female hormone, a follicular hormone estradiol and/or its derivative or a progestational hormone norethisterone and/or its derivative. The external patch comprises an acrylic pressure-sensitive adhesive containing 0.01 to 1% by weight of an isocyanate-based crosslinking agent as an essential ingredient.Type: GrantFiled: August 7, 2003Date of Patent: February 28, 2012Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Takaya Sugahara, Sadanobu Shirai, Masahiro Yamaji
-
Patent number: 8029820Abstract: A patch containing tulobuterol in the low concentration and having the stable release-controllability, prepared by laminating an adhesive layer consisting of a rubber, an adhesive resin and a plasticizer on a backing, wherein 1 to 4 w/w % of tulobuterol in the lower concentration as an active ingredient and 0.1 to 3 w/w % of a higher fatty acid as a drug-releasing controlling agent are contained in the adhesive layer.Type: GrantFiled: June 16, 2004Date of Patent: October 4, 2011Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Sadanobu Shirai, Masahiro Yamaji, Osamu Yoshimoto, Mamoru Naruse, Kenichi Hattori, Takako Sueda
-
Patent number: 8012940Abstract: To control neuropathic pain produced by various mechanisms. Disclosed is a composition for elimination, relief or reduction of neuropathic pain comprising, as an active ingredient, at least one substance selected from the group consisting of D-allose, a derivative of D-allose, D-psicose and a derivative of D-psicose preferably in an amount of 0.01 to 90% by weight. The composition may comprise a mixture of D-allose and/or a derivative thereof and D-psicose and/or a derivative thereof at a ratio of 1:1 to 10:1. The neuropathic pain may be one induced by a disease selected from the group consisting of trigeminal neuralgia, postoperative pain, periodontitis, gingivitis, gingivostomatitis, oral ulcer, herpes zoster, postherpetic neuralgia, diabetic neuritis, causalgia, phantom limb pain and malignant tumor. Also disclosed is use of the composition for elimination, relief or reduction of neuropathic pain by administering the composition to a patient with neuropathic pain in such an amount that 0.Type: GrantFiled: July 20, 2006Date of Patent: September 6, 2011Assignees: Teikoku Seiyaku Co., Ltd., National University Corporation Kagawa UniversityInventor: Mitsuhiro Nagata
-
Patent number: 7988990Abstract: A thin aqueous cataplasm prepared by laminating an adhesive layer (base) having specified constituents on a support which consists of a fiber film prepared by heat-fusing a soft plastic resin on a composite fiber prepared by entangling a natural fiber and a soft plastic fiber, or consists of a fiber film prepared by heat-fusing a plastic resin having a soft part and a hard part in common on a fiber consisting of a plastic having a soft part and hard part in common. The thin aqueous cataplasm retains a moisture-protecting effect on the skin and provides comfortable feeling in its use.Type: GrantFiled: January 26, 2004Date of Patent: August 2, 2011Assignee: Teikoku Seiyaku Co., Ltd.Inventor: Sadanobu Shirai
-
Publication number: 20110184066Abstract: A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000.Type: ApplicationFiled: March 24, 2009Publication date: July 28, 2011Applicant: Teikoku Seiyaku Co., Ltd.Inventor: Masahiro Inazuki
-
Publication number: 20110160194Abstract: An external preparation that effectively produces the anti-inflammatory analgesic effect of a non-steroidal anti-inflammatory analgesic agent, and reduces skin irritation on the application site of the preparation and has an excellent effect on pain associated with inflammation such as chronic rheumatoid arthritis, osteoarthritis, and also lumbago is provided. The external preparation includes a non-steroidal anti-inflammatory analgesic agent and oxybuprocaine or a pharmaceutically acceptable salt thereof. The external preparation includes the non-steroidal anti-inflammatory analgesic agent at a content of 0.1 to 10 wt % based on the total weight of the formulation and oxybuprocaine or a pharmaceutically acceptable salt thereof at a content of 0.01 to 60 wt % based on the total weight of the formulation.Type: ApplicationFiled: June 12, 2009Publication date: June 30, 2011Applicant: TEIKOKU SEIYAKU CO., LTDInventors: Katsuyuki Inoo, Mitsuhiro Kawada
-
Publication number: 20110124727Abstract: An analgesic/antipruritic external preparation that includes a local anesthetic, has fewer side effects, and has an excellent therapeutic effect on pain and itching of the skin is provided. The analgesic/antipruritic external preparation includes oxybuprocaine or a pharmaceutically acceptable salt thereof as an active ingredient, and the oxybuprocaine or a pharmaceutically acceptable salt thereof is contained in an amount of 0.1 to 60 wt %, more preferably 1 to 40 wt %, and most preferably 5 to 30 wt %. The analgesic/antipruritic external preparation has a dosage form as an external preparation wherein the dosage form is an ointment, a solution, a suspension, an emulsion, a lotion, a cataplasm, a tape, an aerosol, or a powder for external use.Type: ApplicationFiled: June 12, 2009Publication date: May 26, 2011Applicant: Teikoku Seiyaku Co., LTDInventors: Katsuyuki Inoo, Mitsuhiro Kawada, Kenjiro Mori
-
Publication number: 20110104215Abstract: Disclosed is a novel transdermally absorbable preparation which enables the efficient, stable and long-term administration of a drug to a living body. More specifically, the transdermally absorbable preparation comprises: a laminate comprising an outer film, a drug-containing layer and a support layer laminated in this order from the side to be contacted with the skin; and a fixing means for fixing the laminate on the skin. In the transdermally absorbable preparation, the outer film is a drug-permeable polymer film that can control the release of the drug into the skin and is provided as a surface of the laminate which is to be contact with the skin.Type: ApplicationFiled: March 25, 2009Publication date: May 5, 2011Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Takeshi Ito, Miho Ishigure
-
Publication number: 20110097407Abstract: Disclosed is a water-based adhesive skin patch which has excellent storage stability, can achieve excellent accumulation of butenafine hydrochloride contained therein on a patched area such as the skin and a nail, and has a high therapeutic effect. Specifically disclosed is a water-based adhesive skin patch containing butenafine hydrochloride, which is characterized by containing butenafine hydrochloride, glycol salicylate and propylene glycol in a water-containing gel ointment. Specifically, butenafine hydrochloride is dissolved in a mixed solution of glycol salicylate and propylene glycol, and the resulting solution is dispersed in a water-containing gel. Particularly, the mixing ratio of glycol salicylate to propylene glycol is 1:2 to 1:30.Type: ApplicationFiled: March 24, 2009Publication date: April 28, 2011Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Takashi Kamakura, Takefumi Hoshikawa, Yukiko Inamoto, Kayo Tanigawa
-
Patent number: 7906487Abstract: A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is a rare saccharide belonging to aldose and/or ketose. The aldose is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells. The ketose is D-psicose, and the cells are selected from the group consisting of chemokine secretion inhibitory activity sensitive cells, microglia migration inhibitory activity sensitive cells, and hypoglycemic activity sensitive cells.Type: GrantFiled: May 22, 2003Date of Patent: March 15, 2011Assignees: Fushimi Pharmaceutical Co., Ltd., Teikoku Seiyaku Co., Ltd., National University Corporation Kagawa University, Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Ken Izumori, Masaaki Tokuda, Toshifumi Itano, Osamu Miyamoto, Toshihiko Ishida, Koji Murao, Taizo Tasaka, Gan Muneuchi, Fuminori Yamaguchi, Terukazu Tanaka, Masaaki Ueki, Kazuyuki Hirooka, Tomohiko Taminato, Mohammad Akram Hossain, Keiji Tsusaki, Takeo Takahashi, Mitsuhiro Nagata, Yutaka Ishida